Literature DB >> 11236131

Immune-derived opioids and peripheral antinociception.

P J Cabot1.   

Abstract

1. Recent findings have suggested a significant involvement of the immune system in the control of pain. Immune cells contain opioid peptides that are released within inflamed tissue and act at opioid receptors on peripheral sensory nerve endings. It is also apparent that different types of lymphocytes contain beta-endorphin, memory T cells containing more beta-endorphin than naïve cells. 2. These findings highlight an integral link between immune cell migration and inflammatory pain. The present review highlights immune system involvement in the site-directed control of inflammatory pain. 3. Full-length mRNA transcripts for opioid precursor proteins are expressed in immune cells. Increased expression of pro-opiomelanocortin mRNA and beta-endorphin has been demonstrated in stimulated lymphocytes and lymphocytes from animals with inflammation. 4. Cytokines and corticotropin-releasing factor (CRF) release opioids from immune cells. Potent peripheral analgesia due to direct injection of CRF can be blocked by antagonists to CRF, antibodies to opioid peptides, antisense to CRF and opioid receptor-specific antagonists. The release of opioid peptides from lymphocytes is calcium dependent and opioid receptor specific. Furthermore, endogenous sources of opioid peptides produce potent analgesia when implanted into the spinal cord. 5. Activated immune cells migrate directly to inflamed tissue using cell adhesion molecules to adhere to the epithelial surface of the vasculature in inflamed tissue. Lymphocytes that have been activated can express opioid peptides. Memory type T cells that contain opioid peptides are present within inflamed tissue; naive cells are not present in inflamed tissue and do not contain opioid peptides. Inhibiting the migration of memory type T cells into inflamed tissue by blocking selectins results in reduced numbers of beta-endorphin-containing cells, a reduced quantity of beta-endorphin in inflamed paws and reduced stress- and CRF-induced peripheral analgesia. 6. Immunosuppression is associated with increased pain in patients. Moreover, immunosuppression results in decreased lymphocyte numbers as well as decreased analgesia in animal models.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11236131     DOI: 10.1046/j.1440-1681.2001.03425.x

Source DB:  PubMed          Journal:  Clin Exp Pharmacol Physiol        ISSN: 0305-1870            Impact factor:   2.557


  13 in total

Review 1.  Peripheral opioid analgesia: clinical applications.

Authors:  Jochen Oeltjenbruns; Michael Schäfer
Journal:  Curr Pain Headache Rep       Date:  2005-02

Review 2.  [Potential applications and significance of peripheral opioid analgesia].

Authors:  J Oeltjenbruns; M Schäfer
Journal:  Schmerz       Date:  2005-10       Impact factor: 1.107

Review 3.  Perspective is everything: an irreverent discussion of CNS-immune system interactions as viewed from different scientific traditions.

Authors:  Monica J Carson; David D Lo
Journal:  Brain Behav Immun       Date:  2007-01-17       Impact factor: 7.217

4.  Peripheral interactions between cannabinoid and opioid systems contribute to the antinociceptive effect of crotalphine.

Authors:  F C Machado; V O Zambelli; A C O Fernandes; A S Heimann; Y Cury; G Picolo
Journal:  Br J Pharmacol       Date:  2014-02       Impact factor: 8.739

5.  Peripheral delta opioid receptors require priming for functional competence in vivo.

Authors:  Matthew P Rowan; Nikita B Ruparel; Amol M Patwardhan; Kelly A Berg; William P Clarke; Kenneth M Hargreaves
Journal:  Eur J Pharmacol       Date:  2008-11-25       Impact factor: 4.432

6.  Early systemic granulocyte-colony stimulating factor treatment attenuates neuropathic pain after peripheral nerve injury.

Authors:  Po-Kuan Chao; Kwok-Tung Lu; Yun-Lin Lee; Jin-Chung Chen; Hung-Li Wang; Yi-Ling Yang; Mei-Yun Cheng; Ming-Feng Liao; Long-Sun Ro
Journal:  PLoS One       Date:  2012-08-24       Impact factor: 3.240

7.  The expression of corticotropin-releasing factor and its receptors in the spinal cord and dorsal root ganglion in a rat model of neuropathic pain.

Authors:  Eun Hyun Kim; Da Hye Ryu; Sejin Hwang
Journal:  Anat Cell Biol       Date:  2011-03-31

8.  Endogenous opioid analgesia in peripheral tissues and the clinical implications for pain control.

Authors:  Daniel Kapitzke; Irina Vetter; Peter J Cabot
Journal:  Ther Clin Risk Manag       Date:  2005-12       Impact factor: 2.423

9.  Dynorphin 1-17 and Its N-Terminal Biotransformation Fragments Modulate Lipopolysaccharide-Stimulated Nuclear Factor-kappa B Nuclear Translocation, Interleukin-1beta and Tumor Necrosis Factor-alpha in Differentiated THP-1 Cells.

Authors:  Siti Sarah Fazalul Rahiman; Michael Morgan; Paul Gray; Paul Nicholas Shaw; Peter John Cabot
Journal:  PLoS One       Date:  2016-04-07       Impact factor: 3.240

10.  Targeting peripheral opioid receptors to promote analgesic and anti-inflammatory actions.

Authors:  Katerina S Iwaszkiewicz; Jennifer J Schneider; Susan Hua
Journal:  Front Pharmacol       Date:  2013-10-24       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.